Discover undervalued stocks with Eulerpool.

Subscribe for $2

Edwards Lifesciences Stock EW

Price

0
Today +/-
-0
Today %
-0 %

Edwards Lifesciences stock price

Loading chart...
Weekly
Details

Price

ⓘ

Overview

The Quote Chart provides detailed and dynamic insights into the Edwards Lifesciences stock's performance, showcasing daily, weekly, or monthly aggregated quotes. Users can switch between different time frames to analyze the stock's progression meticulously and make informed investment decisions.

Intraday Feature

The intraday feature provides real-time data, allowing investors to view the Edwards Lifesciences stock’s price fluctuations within the trading day, facilitating timely and strategic investment decisions.

Total Return and Relative Price Change

View the total return of the Edwards Lifesciences stock to gauge its profitability over time. The relative price change, based on the first quote available in the selected timeframe, offers insights into the stock’s performance, assisting in evaluating its investment potential.

Interpretation and Investment

Utilize the comprehensive data presented in the Quote Chart to analyze Edwards Lifesciences's market trends, price movements, and potential returns. Make informed investment choices by comparing different time frames and evaluating intraday data for optimized portfolio management.

Edwards Lifesciences Stock Price History

DateEdwards Lifesciences Price
10/6/20250 undefined
10/6/202577.24 undefined
10/3/202577.46 undefined
10/2/202575.98 undefined
10/1/202576.74 undefined
9/30/202577.78 undefined
9/28/202577.19 undefined
9/25/202576.25 undefined
9/24/202575.27 undefined
9/24/202574.67 undefined
9/23/202574.58 undefined
9/22/202573.87 undefined
9/19/202574.42 undefined
9/18/202574.56 undefined
9/17/202575.21 undefined
9/16/202575.10 undefined
9/15/202576.61 undefined
9/12/202577.58 undefined
9/11/202577.98 undefined
9/10/202578.29 undefined
9/9/202579.81 undefined
9/8/202580.22 undefined

Edwards Lifesciences Revenue, EBIT, Net Income

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Details

Revenue, EBIT and Profit

ⓘ

Understanding Revenue, EBIT, and Income

Gain insights into Edwards Lifesciences, a comprehensive overview of its financial performance can be obtained by analyzing the Revenue, EBIT, and Income chart. Revenue represents the total income generated by Edwards Lifesciences from its primary operations, showcasing the company’s ability to attract and retain clients. EBIT, or Earnings Before Interest and Taxes, indicates the company’s operational profitability, free from the influence of tax and interest expenses. The Income section reflects Edwards Lifesciences’s net earnings, an ultimate measure of its financial health and profitability.

Yearly Analysis and Comparisons

Observe the yearly bars to understand the annual performance and growth of Edwards Lifesciences. Compare the Revenue, EBIT, and Income to evaluate the company’s efficiency and profitability. A higher EBIT compared to the previous year suggests an improvement in operational efficiency. Likewise, an increase in Income indicates enhanced overall profitability. Analyzing the year-to-year comparison assists investors in understanding the company’s growth trajectory and operational efficiency.

Utilizing Expectations for Investment

The expected values for the forthcoming years offer investors a glimpse into Edwards Lifesciences’s anticipated financial performance. Analyzing these projections alongside historical data aids in making informed investment decisions. Investors can gauge the potential risks and returns, aligning their investment strategies accordingly to optimize profitability and mitigate risks.

Investment Insights

Leveraging the comparison between Revenue and EBIT helps in assessing Edwards Lifesciences’s operational efficiency, while the Revenue and Income comparison reveals the net profitability after accounting for all expenses. Investors can derive valuable insights by meticulously analyzing these financial parameters, laying the foundation for strategic investment decisions aimed at capitalizing on Edwards Lifesciences’s growth potential.

Edwards Lifesciences Revenue, EBIT and net profit per share

DateEdwards Lifesciences RevenueEdwards Lifesciences EBITEdwards Lifesciences Net Income
2030e9.83 B undefined0 undefined2.73 B undefined
2029e8.89 B undefined2.71 B undefined2.46 B undefined
2028e8.17 B undefined2.39 B undefined2.21 B undefined
2027e7.45 B undefined2.13 B undefined1.94 B undefined
2026e6.76 B undefined1.89 B undefined1.72 B undefined
2025e6.16 B undefined1.67 B undefined1.54 B undefined
20245.44 B undefined1.48 B undefined4.17 B undefined
20235.01 B undefined1.51 B undefined1.4 B undefined
20224.46 B undefined1.57 B undefined1.52 B undefined
20215.23 B undefined1.71 B undefined1.5 B undefined
20204.39 B undefined1.3 B undefined823.4 M undefined
20194.35 B undefined1.25 B undefined1.05 B undefined
20183.72 B undefined1.08 B undefined722.2 M undefined
20173.44 B undefined1.02 B undefined583.6 M undefined
20162.96 B undefined813.7 M undefined569.5 M undefined
20152.49 B undefined643.4 M undefined494.9 M undefined
20142.32 B undefined487.9 M undefined811.1 M undefined
20132.05 B undefined473.1 M undefined389.1 M undefined
20121.9 B undefined420.1 M undefined291.5 M undefined
20111.68 B undefined301.4 M undefined236.7 M undefined
20101.45 B undefined291.4 M undefined218 M undefined
20091.32 B undefined237.7 M undefined229.1 M undefined
20081.24 B undefined199.9 M undefined128.9 M undefined
20071.09 B undefined174.9 M undefined113 M undefined
20061.04 B undefined172.8 M undefined130.5 M undefined
2005997.9 M undefined175.4 M undefined79.3 M undefined

Edwards Lifesciences Income Statement, Balance Sheet, Cash Flow Statement

  • Simple

  • Expanded

  • Income Statement

  • Balance Sheet

  • Cashflow

 
REVENUE (B)
REVENUE GROWTH (%)
GROSS MARGIN (%)
GROSS INCOME (B)
NET INCOME (B)
NET INCOME GROWTH (%)
SHARES (M)
DOCUMENTS
19971998199920002001200220032004200520062007200820092010201120122013201420152016201720182019202020212022202320242025e2026e2027e2028e2029e2030e
0.880.870.910.80.690.70.860.9311.041.091.241.321.451.681.92.052.322.492.963.443.724.354.395.234.465.015.446.166.767.458.178.899.83
--1.594.62-11.16-13.931.7322.168.267.094.015.2113.386.799.5415.9613.177.6913.557.3618.8515.938.3616.820.8719.29-14.6812.238.5613.249.7610.259.558.8910.57
47.3346.1348.5147.3953.1857.3958.2660.2662.4963.9365.2666.1369.8071.7370.8074.1474.7273.0875.2573.1074.5374.7774.3675.3576.1383.7880.4679.4670.1763.9357.9952.9348.6143.96
0.420.40.440.380.370.40.50.560.620.660.710.820.921.041.191.411.531.71.882.172.562.783.233.313.983.744.034.32000000
-0.050.060.08-0.27-0.010.060.0800.080.130.110.130.230.220.240.290.390.810.490.570.580.721.050.821.51.521.44.171.541.721.942.212.462.73
--219.2332.26-431.71-95.96-600.0043.64-98.737,800.0064.56-13.0813.2778.91-4.808.2623.3133.68108.48-39.0915.182.4623.8444.88-21.3282.621.20-7.82197.72-63.0611.6112.5514.0911.2211.07
696.5696.5696.5700.2706.8735.6733.2744747.6766.8752.4715.2705715.2716.4709.8682.8651660.9653.4647.7640.8636.6631.9631.2624.2609.4599.3000000
- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -
Details

Keystats

ⓘ

Revenue and Growth

The Edwards Lifesciences Revenue and Revenue Growth are pivotal to understanding the company's financial health and operational efficiency. A consistent increase in revenue indicates a company’s ability to effectively market and sell its products or services, while the revenue growth percentage offers insights into the pace at which the company is expanding over the years.

Gross Margin

The Gross Margin is a crucial metric that showcases the percentage of revenue exceeding the cost of goods sold (COGS). A higher gross margin is indicative of a company’s efficiency in controlling its production costs, thereby promising potential profitability and financial stability.

EBIT and EBIT Margin

EBIT (Earnings Before Interest and Taxes) and EBIT Margin offer deep insights into a company’s profitability, excluding the impacts of interest and taxes. Investors often assess these metrics to gauge the operational efficiency and inherent profitability of a business, separate from its financial structure and tax environment.

Income and Growth

Net Income and its subsequent growth are quintessential for investors looking to understand a company’s profitability. Consistent income growth underscores a company’s ability to enhance its profitability over time, reflecting operational efficiency, strategic competitiveness, and financial health.

Shares Outstanding

Shares outstanding refer to the total number of shares a company has issued. It's instrumental in calculating key metrics like Earnings Per Share (EPS) which is pivotal for investors to evaluate a company’s profitability on a per-share basis, offering a more granular view of financial health and valuation.

Interpreting Year to Year Comparison

Comparing yearly data allows investors to identify trends, assess the company’s growth, and anticipate potential future performance. Analyzing how metrics like revenue, income, and margins change year over year can provide valuable insights into the company’s operational efficiency, competitiveness, and overall financial health.

Expectations and Predictions

Investors often juxtapose the current and past financial data with the market’s expectations. This comparison aids in assessing whether the Edwards Lifesciences is performing as anticipated, underperforming or outperforming the market predictions, providing pivotal data for investment decisions.

 
ASSETS
CASH BALANCE (B)
RECEIVABLES (M)
OTHER REC. (M)
INVENTORIES (B)
OTHER CURRENT LIAB. (M)
CURRENT ASSETS (B)
TANGIBLE ASSETS (B)
LONG-T. INVEST. (B)
LONG-T. REC. (M)
INTANGIBLE ASSETS (B)
GOODWILL (B)
OTHER NON-CURRENT ASSETS (B)
NON-CURRENT ASSETS (B)
TOTAL ASSETS (B)
LIABILITIES
COMMON STOCK (M)
ADDITIONAL PAID-IN CAPITAL (B)
RETAINED EARNINGS (B)
OTHER EQUITY (M)
UNREAL. GAINS/LOSSES (M)
EQUITY (B)
LIABILITIES (B)
PROVISIONS (M)
OTHER SHORT-TERM LIAB. (M)
SHORT-TERM DEBTS (M)
LONG-TERM DEBT PORTION (M)
SHORT-TERM REC. (B)
LONG-T. LIAB. (M)
DEFERRED TAXES (M)
OTHER LIAB. (B)
LONG-T. LIABILITIES (B)
DEBT (B)
TOTAL CAPITAL (B)
199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024
                                                     
000.030.050.030.060.050.180.180.190.230.330.40.450.520.941.441.221.271.340.961.521.41.471.221.643.98
1411331078588.397.5104.1101.1111.5115.8186.3249.4277.3283.8321.1302.5288315.4414.6438.7456.9543.6514.6582.2643775.1609.1
2822221520.12115.317.415.629.518.422.725.236.926.425.53756.4040.680.455.588.282.756.161.8118.3
0.160.170.090.090.110.120.130.130.140.150.150.170.20.260.280.310.30.340.40.550.610.640.80.730.881.171.09
2832575765.860.171.585.679.697.3108.6117.1130.4136142152170.5111.5157.7177.5186.1227.1283.3322.3305.9386.1495.4
0.350.360.30.290.320.360.370.510.530.590.690.891.031.171.291.732.232.052.242.552.292.983.093.183.14.046.29
0.230.230.180.190.210.210.20.20.210.230.230.250.270.30.370.420.440.480.580.680.871.141.491.641.731.841.78
000.10.090.020.040.020.010.020.030.010.020.030.020.020.020.240.380.530.570.510.590.81.831.240.580.31
000000000000024.69.97.35.80000000000
0.110.10.080.070.070.080.150.140.120.120.10.090.070.070.070.030.020.210.20.470.340.340.330.320.290.431.18
0.780.740.430.330.330.340.340.340.340.350.320.320.320.350.380.390.380.630.631.131.111.171.171.171.161.251.78
0.020.020.010.010.050.080.030.030.030.030.050.050.060.040.070.110.20.310.330.280.210.270.350.360.781.221.72
1.131.080.810.690.680.740.750.710.720.760.710.730.730.810.930.981.292.012.273.123.043.54.155.325.25.336.77
1.481.441.110.9811.11.111.231.251.351.41.621.771.982.222.713.524.064.515.675.326.497.248.58.299.3613.06
                                                     
00595960.262.664.265.66768.673.776.1117120124.2126128.9239.1242.6212215.2218.1636.4642646.3650.5654.8
000.280.290.410.460.50.540.60.680.941.060.210.30.490.670.880.951.171.171.381.621.441.71.972.272.61
0.340.420.10.090.140.220.220.30.430.550.680.911.121.361.652.032.843.343.911.962.693.744.576.077.598.9913.17
935806126-44.7-32.2-20.8-22.2-15.87.5-35.4-7.9-42.1-37.5-39.3-27.9-100.9-181.1-198.4-128.1-133.5-157.7-169.7-150.8-189.3-218-240.5
000000000000001.40.30-1.50-4.6-51.78.6-6.9-65.6-24.8-4
1.271.220.440.460.570.720.770.881.091.311.662.031.411.742.232.83.754.345.123.214.165.436.488.259.9511.6716.19
0.040.040.060.050.070.070.060.060.050.060.070.050.050.090.070.330.060.070.10.120.130.180.20.20.21.370.25
113114114130107.8116.8113108.3140.3161.5186.7203.5205.6219.6263.20340378.4418.4516.1510.2642.7578.7714.2667.8819.7856.6
00000020.425.2374.76.235.942.830.69.513.230.528.517189.3232.479.3118.7113.6152.7174.3397.5
00611000001500041.800000000000000
00000000000000000005980000000
0.160.160.240.180.180.180.20.190.230.380.260.290.340.340.350.350.430.480.531.420.880.90.891.031.022.371.51
00367310245.5255.8267.1316.1235.961.7175.590.30150.4189.3593.1598.1596.9822.3438.4593.8594.4595595.7596.3597597.7
000000000000000126.4194.8194.700124.9171.7214.40000
0.060.060.060.030.040.030.020.030.040.070.090.080.120.160.210.10.110.290.540.850.590.670.961.040.870.850.89
0.060.060.430.340.290.280.290.340.270.130.260.170.120.310.390.820.911.081.361.291.311.441.771.631.461.451.49
0.210.210.670.520.470.470.480.540.50.510.520.460.460.640.741.171.331.551.892.712.182.342.662.672.493.812.99
1.481.441.110.981.041.181.251.421.591.822.182.491.872.392.973.975.085.897.015.926.347.779.1410.9212.4415.4919.18
Details

Balance Sheet

ⓘ

Understanding the Balance Sheet

The balance sheet of Edwards Lifesciences provides a detailed financial snapshot, revealing the company's assets, liabilities, and equity at a specific point in time. Analyzing these components is crucial for investors looking to understand Edwards Lifesciences's financial health and stability.

Assets

Edwards Lifesciences's assets represent everything the company owns or controls that has monetary value. These are categorized into current and non-current assets, offering insights into the company's liquidity and long-term investments.

Liabilities

Liabilities are obligations that Edwards Lifesciences must settle in the future. Analyzing the ratio of liabilities to assets provides insights into the company's financial leverage and risk exposure.

Equity

Equity refers to the residual interest in the assets of Edwards Lifesciences after deducting liabilities. It represents the owners’ claim on the company’s assets and earnings.

Year-to-Year Analysis

Comparing balance sheet figures year-to-year allows investors to identify trends, growth patterns, and potential financial risks, facilitating informed investment decisions.

Interpreting the Data

Detailed analysis of assets, liabilities, and equity can provide investors with comprehensive insights into Edwards Lifesciences's financial standing, aiding in investment evaluations and risk assessments.

 
NET INCOME (B)
DEPRECIATION (M)
DEFERRED TAXES (M)
CHANGES IN WORKING CAPITAL (M)
NON-CASH ITEM (M)
PAID INTEREST (M)
PAID TAXES (M)
NET CASH FLOW FROM OPERATING ACTIVITIES (B)
CAPITAL EXPENDITURES (M)
CASH FLOW FROM INVESTING ACTIVITIES (M)
CASH FLOW FROM OTHER INVESTING ACTIVITIES (M)
INTEREST INCOME AND EXPENSES (M)
NET DEBT CHANGE (M)
NET CHANGE IN EQUITY (M)
CASH FLOW FROM FINANCING ACTIVITIES (M)
CASH FLOW FROM OTHER FINANCING ACTIVITIES (M)
TOTAL DIVIDENDS PAID (M)
NET CHANGE IN CASH FLOW (M)
FREE CASH FLOW (M)
SHARE-BASED COMPENSATION (M)
199719981999200020012002200320042005200620072008200920102011201220132014201520162017201820192020202120222023
-0.050.060.08-0.27-0.010.060.0800.080.130.110.130.230.220.240.290.390.810.490.570.580.721.050.821.51.521.4
8082847457404555565654555856585362686571817789107134139144
0000-30-1350-137-5-23-4-110-26-12-71-95-3717-2712-49-41-254-272
6-4-2-123-9-132-3-125-69-68-1-2947521906466234-42-20442145-421-526
129141234782772511918504590-211885372871699114426831622399359289
0001719911121210972234415171619301919201919
00061010141137143137341415000869914322361197182504470
0.160.150.180.140.10.150.140.180.140.230.210.150.170.250.310.360.471.020.550.710.931.181.051.731.220.9
-42-40-42-46-46-47-44-53-51-59-62-78-64-63-90-116-110-93-106-217-175-241-278-407-329-264-266
-58-52-49-75-4-68-76-177-27-37-1475840-61-412-78-412-633-316-211-64776-595-531-1,722252173
-16-12-7-2942-20-32-1232321-841361041-32237-302-539-2095-471318-317-123-1,392517440
000000000000000000000000000
000441-91-81-4759-85-2794-84-4810439409-121222176-437-100-100
00000-17-12-28-27-112-92-242-28-107-243-244-451-187-192-559-649-648-102-484-354-1,580-709
-105-102-127-37-78-99-21-2029-193-108-134-91-103-135-15534-153-158-268-473-1,101-115-486-356-1,584-711
-105-102-127-47813-1-41-2412142152448764732680-15-2-10-3-1
000000000000000000000000000
0002820-1326-121294-417611562-22413910923364211-111-10446515-332-94375
1211141349155102.897.6127.185.8173.3150.675.2101.3188.4223.9246.1362.6928.6443.2487825.2685.19016471,402.3953.4629.5
000000000000000000000000000

Edwards Lifesciences stock margins

The Edwards Lifesciences margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Edwards Lifesciences. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Edwards Lifesciences.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Details

Margin

ⓘ

Understanding Gross Margin

The gross margin, expressed as a percentage, delineates the gross profit made from the Edwards Lifesciences's sales revenue. A higher gross margin percentage indicates that the Edwards Lifesciences retains more revenue after accounting for the costs of goods sold. Investors use this metric to gauge financial health and operational efficiency, as well as to compare it with competitors and industry averages.

EBIT Margin Analysis

EBIT margin represents the Edwards Lifesciences's earnings before interest and taxes. Analyzing the EBIT margin over different years provides insights into the operational profitability and efficiency, excluding the effects of financial leverage and tax structure. A growing EBIT margin over the years signifies improving operational performance.

Revenue Margin Insights

The revenue margin demonstrates the Edwards Lifesciences's total revenue generated. When comparing the revenue margin year over year, investors can gauge the Edwards Lifesciences's growth and market expansion. It is essential to compare the revenue margin with the gross and EBIT margins to understand the cost and profit structures better.

Interpreting Expectations

The expected values for gross, EBIT, and revenue margins provide future financial outlook of the Edwards Lifesciences. Investors should compare these expectations with historical data to understand potential growth and risk factors. It is crucial to consider the underlying assumptions and methodologies used in projecting these expected values to make informed investment decisions.

Comparative Analysis

Comparing the gross, EBIT, and revenue margins, both yearly and over multiple years, enables investors to perform a comprehensive analysis of the Edwards Lifesciences's financial health and growth prospects. Evaluating the trends and patterns in these margins helps in identifying strengths, weaknesses, and potential investment opportunities.

Edwards Lifesciences Margin History

Edwards Lifesciences Gross marginEdwards Lifesciences Profit marginEdwards Lifesciences EBIT marginEdwards Lifesciences Profit margin
2030e79.46 %0 %27.77 %
2029e79.46 %30.51 %27.66 %
2028e79.46 %29.32 %27.07 %
2027e79.46 %28.53 %25.99 %
2026e79.46 %27.9 %25.47 %
2025e79.46 %27.16 %25.05 %
202479.46 %27.21 %76.75 %
202380.47 %30.19 %27.99 %
202283.79 %35.28 %34.09 %
202176.13 %32.7 %28.73 %
202075.36 %29.71 %18.77 %
201974.37 %28.68 %24.08 %
201874.77 %28.97 %19.4 %
201774.52 %29.69 %16.99 %
201673.09 %27.46 %19.22 %
201575.25 %25.8 %19.85 %
201473.07 %21 %34.92 %
201374.74 %23.13 %19.02 %
201274.15 %22.12 %15.35 %
201170.82 %17.96 %14.1 %
201071.78 %20.14 %15.07 %
200969.8 %17.99 %17.34 %
200866.1 %16.15 %10.41 %
200765.34 %16.03 %10.36 %
200663.97 %16.66 %12.58 %
200562.46 %17.58 %7.95 %

Edwards Lifesciences Stock Sales Revenue, EBIT, Earnings per Share

The Edwards Lifesciences earnings per share therefore indicates how much revenue Edwards Lifesciences has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Sales per Share
EBIT per share
Earnings per Share
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Edwards Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Edwards Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Edwards Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Edwards Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Edwards Lifesciences Revenue, EBIT and net profit per share

DateEdwards Lifesciences Sales per ShareEdwards Lifesciences EBIT per shareEdwards Lifesciences Earnings per Share
2030e16.41 undefined0 undefined4.56 undefined
2029e14.84 undefined0 undefined4.1 undefined
2028e13.62 undefined0 undefined3.69 undefined
2027e12.44 undefined0 undefined3.23 undefined
2026e11.28 undefined0 undefined2.87 undefined
2025e10.28 undefined0 undefined2.57 undefined
20249.08 undefined2.47 undefined6.97 undefined
20238.22 undefined2.48 undefined2.3 undefined
20227.15 undefined2.52 undefined2.44 undefined
20218.29 undefined2.71 undefined2.38 undefined
20206.94 undefined2.06 undefined1.3 undefined
20196.83 undefined1.96 undefined1.64 undefined
20185.81 undefined1.68 undefined1.13 undefined
20175.3 undefined1.57 undefined0.9 undefined
20164.54 undefined1.25 undefined0.87 undefined
20153.77 undefined0.97 undefined0.75 undefined
20143.57 undefined0.75 undefined1.25 undefined
20133 undefined0.69 undefined0.57 undefined
20122.68 undefined0.59 undefined0.41 undefined
20112.34 undefined0.42 undefined0.33 undefined
20102.02 undefined0.41 undefined0.3 undefined
20091.87 undefined0.34 undefined0.32 undefined
20081.73 undefined0.28 undefined0.18 undefined
20071.45 undefined0.23 undefined0.15 undefined
20061.35 undefined0.23 undefined0.17 undefined
20051.33 undefined0.23 undefined0.11 undefined

Edwards Lifesciences business model

Edwards Lifesciences Corp is a globally operating company in the field of medical technology, specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. The company was founded in California in 1958 and is now one of the leading companies in the field of modern heart valve technology. The history of Edwards Lifesciences begins with its founding by Miles "Lowell" Edwards and his longtime employee Dr. Albert Starr. They recognized the need for a less invasive and more effective alternative to heart valves than the existing surgical methods. They received their first patent in 1960 and performed their first successful heart valve operation on a sheep in the same year. The first surgeries on humans took place in 1962. Edwards Lifesciences quickly expanded in the US and internationally. The business model of Edwards Lifesciences focuses on three business areas: "Transcatheter Heart Valve Systems," "Surgical Heart Valve Therapy," and "Critical Care." Each area is focused on a specific range of products and is supported by its own team of professionals. The "Transcatheter Heart Valve Systems" area has become the most important division of Edwards Lifesciences. This novel technology enables the implantation of an artificial heart valve system through minimally invasive surgical methods, without the need for an open procedure. The system consists of a foldable heart valve made of animal tissue or artificial material, which is inserted into the damaged heart through a catheter. This method is applicable to a wide range of patients and has become an important tool in the treatment of heart diseases. The "Surgical Heart Valve Therapy" business area includes implantable mechanical and biological heart valves for open surgical procedures. Edwards Lifesciences develops innovative products to meet the needs of surgical patients and doctors. The third business area, "Critical Care," offers instruments and technologies for the critical medical care of patients in intensive care units and emergency departments. The company manufactures collagen matrix products for wound care, catheter monitoring systems, and patient monitoring devices to detect potential life-threatening complications early. Over the years, Edwards Lifesciences has introduced numerous innovative products to the market that are used in medical practice. The Edwards SAPIEN Transcatheter Heart Valve System was approved in Europe in 2011 and in the US in 2012 and has since improved the lives of tens of thousands of patients. With new technologies such as the Edwards SAPIEN 3 and SAPIEN 3 Ultra platforms, the company is constantly striving to increase the effectiveness and safety of heart disease treatment. Edwards Lifesciences is headquartered in Irvine, California, and is a multinational company with locations in North America, Europe, India, and Asia. The company currently employs approximately 14,000 people worldwide and is an important pillar of the medical community. Answer: Edwards Lifesciences Corp is a global medical technology company specializing in the development, production, and distribution of products for the treatment of heart diseases and critical illnesses. It is a leader in modern heart valve technology. Edwards Lifesciences is one of the most popular companies on Eulerpool.com.

Edwards Lifesciences SWOT Analysis

Strengths

  • Edwards Lifesciences Corp is a leading medical technology company specializing in heart valve replacement and hemodynamic monitoring.
  • Strong brand reputation and global market presence.
  • Continuous investment in research and development leading to innovative product portfolio.
  • Strong distribution network and strategic partnerships fostering market growth.
  • Robust financial performance and strong revenue growth in recent years.

Weaknesses

  • Reliance on a limited number of product offerings, with heart valve replacement being the main revenue driver.
  • Vulnerability to fluctuations in healthcare policies and regulations.
  • Limited presence in emerging markets compared to competitors.
  • Competitive pressures from other medical device manufacturers.

Opportunities

  • Growing demand for minimally invasive surgeries and transcatheter heart valve replacement.
  • Increasing prevalence of cardiovascular diseases worldwide, providing a larger target market.
  • Expansion into emerging markets, such as Asia-Pacific and Latin America, to tap into unexplored growth potentials.
  • Potential for acquisitions and strategic partnerships to broaden the product portfolio and expand market reach.
  • Rising healthcare expenditure and aging population driving the demand for advanced medical technologies.

Threats

  • Intense competition within the medical device industry.
  • Price pressures from reimbursement cuts and hospital budget constraints.
  • Regulatory challenges and potential changes in healthcare policies.
  • Economic downturns impacting overall healthcare spending.
  • Potential for new entrants or disruptive technologies affecting market share.

Edwards Lifesciences Revenue by Segment

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Edwards Lifesciences Revenue by Segment

Segmente2017201620152014201320122011
Critical Care-------
Surgical Structural Heart-------
Transcatheter Aortic Valve Replacement-------
Transcatheter Mitral and Tricuspid Therapies-------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Edwards Lifesciences Revenue by Segment

Segmente2017201620152014201320122011
Transcatheter Heart Valve Therapy2.03 B USD1.63 B USD1.18 B USD----
Surgical Heart Valve Therapy807.1 M USD774.9 M USD785 M USD-801.2 M USD787.5 M USD-
Critical Care601 M USD560.3 M USD528.4 M USD-536.6 M USD560 M USD508.3 M USD
Heart Valve Therapy------1.01 B USD
This element represents the transcatheter heart valve therapy product line---943.6 M USD---
This element represents the surgical heart valve therapy product line---826.1 M USD---
This element represents the transcatheter heart valves product line----707.7 M USD--
This element represents the critical care product line---553.2 M USD---
Transcatheter Heart Valves-----552.1 M USD-
Cardiac Surgery Systems------107.5 M USD
Vascular------52.1 M USD
Surgical Structural Heart-------
Transcatheter Aortic Valve Replacement-------
Transcatheter Mitral and Tricuspid Therapies-------

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Segment

The chart visualizes revenues by segments and provides a clear overview of the revenue distribution. Each segment is clearly marked to facilitate comparisons of revenues.

Interpretation and Use

The chart enables quick identification of the highest-revenue segments, which is helpful in strategic decision-making. It supports the analysis of growth potentials and targeted resource allocation.

Investment Strategy

An investment strategy determines how capital is deliberately invested into various asset classes to maximize returns. It is based on risk tolerance, investment objectives, and a long-term plan.

Edwards Lifesciences Revenue by Segment

Segmente2017201620152014201320122011
United States1.91 B USD1.62 B USD1.26 B USD----
Europe800.7 M USD745.9 M USD842.9 M USD--577 M USD549.4 M USD
Operating Segments-----1.92 B USD1.58 B USD
Rest of World357.3 M USD303.6 M USD315.1 M USD-252.8 M USD-200.8 M USD
UNITED STATES-----812.1 M USD605.6 M USD
Represents the United States reportable segment of the entity---1.05 B USD---
United States Segment----939.6 M USD--
Japan356.5 M USD279.6 M USD297.2 M USD----
Represents the Europe reportable segment of the entity---741.4 M USD---
Europe Segment----622.2 M USD--
JAPAN-----293.4 M USD226.8 M USD
Japan Segment----293.7 M USD--
Represents the reportable segment of the entity comprised of regions other than the United States, Europe and Japan (Rest of World)---285.1 M USD---
Represents the Japan reportable segment of the entity---270.8 M USD---
This element represents the Rest of World segment of the entity-----236 M USD-

Edwards Lifesciences Revenue by Region

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Details
Details

Revenue by Segment

ⓘ

Overview of Revenue by Region

The chart shows revenues by region and provides a clear comparison of regional revenue distribution. Each region is clearly marked to illustrate the differences.

Interpretation and Usage

The diagram helps to identify the regions with the highest revenue and to make targeted decisions for regional expansion or investments. It supports the analysis of market potentials and strategic priorities.

Investment Strategy

An investment strategy focused on regions concentrates on the deliberate capital allocation in different markets to optimally use regional growth opportunities. It takes into account market conditions and regional risk factors.

Edwards Lifesciences Revenue by Segment

DateEuropeInternationalJ [P]JapanJAPANRepresents the geographic areas of the world other than the United States, Europe and JapanRest of WorldThis element represents the Rest of World segment of the entityU [S]United States
20231.33 B USD--452.4 M USD--709.2 M USD--3.51 B USD
20221.17 B USD--473.6 M USD--601.4 M USD--3.13 B USD
20211.19 B USD--528.9 M USD--550.2 M USD--2.96 B USD
2020973.6 M USD--460.1 M USD--435.8 M USD--2.52 B USD
2019941.2 M USD--444.7 M USD--429.4 M USD--2.53 B USD
2018885.1 M USD--396.8 M USD--385.6 M USD--2.06 B USD
2017831 M USD--350.3 M USD--346.4 M USD--1.91 B USD
2016749 M USD--309.3 M USD--289.7 M USD--1.62 B USD
2015717.3 M USD--246.2 M USD--267.3 M USD--1.26 B USD
2014744.5 M USD-257.9 M USD--273.2 M USD--1.05 B USD-
2013616.5 M USD--243.6 M USD--245.8 M USD--939.6 M USD
2012559.7 M USD---294.1 M USD--233.7 M USD-812.1 M USD
2011574 M USD---283.7 M USD-215.3 M USD--605.6 M USD
2010-879.4 M USD-------567.6 M USD
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Edwards Lifesciences Eulerpool Fair Value

Details

Fair Value

ⓘ

Understanding Fair Value

The fair value of a stock provides insights into whether the stock is currently undervalued or overvalued. It is calculated based on profit, revenue, or dividends and offers a comprehensive perspective of the stock’s intrinsic value.

Income-Based Fair Value

This is calculated by multiplying the earnings per share by the average P/E ratio of the selected past years for smoothing. If the fair value is higher than the current market price, it suggests that the stock is undervalued.

Example 2022

Fair Value Profit 2022 = Earnings per Share 2022 / Average P/E Ratio 2019 - 2021 (3 Years Smoothing)

Revenue-Based Fair Value

It is derived by multiplying the revenue per share by the average price-to-sales ratio of the selected past years for smoothing. An undervalued stock is identified if the fair value exceeds the ongoing market price.

Example 2022

Fair Value Revenue 2022 = Revenue per Share 2022 / Average PSR 2019 - 2021 (3 Years Smoothing)

Dividend-Based Fair Value

This value is determined by dividing the dividend per share by the average dividend yield of the selected past years for smoothing. A higher fair value than the market price indicates an undervalued stock.

Example 2022

Fair Value Dividend 2022 = Dividend per Share 2022 * Average Dividend Yield 2019 - 2021 (3 Years Smoothing)

Expectations and Forecasts

Future expectations provide potential trajectories for stock prices and aid investors in decision-making. The expected values are forecasted figures of fair value, taking into account the growth or decline trends of profit, revenue, or dividend.

Comparative Analysis

Comparing the fair value based on profit, revenue, and dividend provides a holistic overview of the stock’s financial health. Observing the annual and per-annual variations contributes to understanding the consistency and reliability of stock performance.

Edwards Lifesciences historical P/E ratio, EBIT multiple, and P/S ratio

Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2

Edwards Lifesciences shares outstanding

The number of shares was Edwards Lifesciences in 2024 — This indicates how many shares 599.3 M is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Edwards Lifesciences earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Edwards Lifesciences's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Edwards Lifesciences’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Edwards Lifesciences's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Edwards Lifesciences stock splits

In Edwards Lifesciences's history, there have been no stock splits.
Eulerpool Premium

The World’s Best Investors Are On Eulerpool

Subscribe for $2
Unfortunately, there are currently no price targets and forecasts available for Edwards Lifesciences.

Edwards Lifesciences latest earnings and earnings surprises

DateEPS EstimateEPS ActualQuarterly report
6/30/20250.64 0.67  (4.39 %)2025 Q2
3/31/20250.61 0.64  (4.12 %)2025 Q1
12/31/20240.57 0.59  (3.4 %)2024 Q4
9/30/20240.66 0.67  (1.56 %)2024 Q3
6/30/20240.71 0.7  (-2.08 %)2024 Q2
3/31/20240.66 0.66  (-0.32 %)2024 Q1
12/31/20230.66 0.64  (-2.51 %)2023 Q4
9/30/20230.61 0.59  (-3.29 %)2023 Q3
6/30/20230.67 0.66  (-0.95 %)2023 Q2
3/31/20230.63 0.62  (-0.86 %)2023 Q1
1
2
3
4
5
...
11

Eulerpool ESG Scorecard© for the Edwards Lifesciences stock

Eulerpool World ESG Rating (EESG©)

61/ 100

🌱 Environment

61

👫 Social

68

🏛️ Governance

53

Environment

Scope 1 - Direct Emissions
15,682
Scope 2 - Indirect emissions from purchased energy
31,871
Scope 3 - Indirect emissions within the value chain
571,975
Total CO₂ emissions
47,553
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather
Pesticides
Palm Oil
Tobacco
Genetically modified organisms
Climate concept
Sustainable forestry
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency

Social

Percentage of female employees59
Percentage of women in management
Percentage of Asian employees35.1
Share of Asian management
Percentage of Hispanic/Latino employees16.9
Hispano/Latino Management share
Percentage of Black employees2.9
Black Management Share
Percentage of white employees39
White Management Share
Adult content
Alcohol
Weapons
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept
Occupational health and safety
Catholic

Governance (Corporate Governance)

Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Edwards Lifesciences shareholders

%
Name
Stocks
Change
Date
11.63610 % The Vanguard Group, Inc.69,735,131793,2026/30/2025
5.15437 % BlackRock Institutional Trust Company, N.A.30,890,122-1,392,0686/30/2025
4.27739 % State Street Global Advisors (US)25,634,378-149,0846/30/2025
3.35210 % JP Morgan Asset Management20,089,1563,717,6466/30/2025
3.30827 % Wellington Management Company, LLP19,826,483-9,308,3076/30/2025
2.12436 % Citadel Advisors LLC12,731,291-650,3926/30/2025
2.12288 % Geode Capital Management, L.L.C.12,722,41645,5556/30/2025
1.94744 % Jennison Associates LLC11,670,9911,584,9586/30/2025
1.48691 % Walter Scott & Partners Ltd.8,911,033-150,0666/30/2025
1.43261 % Union Investment Privatfonds GmbH8,585,6164,670,7746/30/2025
1
2
3
4
5
...
10

Edwards Lifesciences Executives and Management Board

Mr. Bernard Zovighian

(56)
Edwards Lifesciences President, Chief Executive Officer
Compensation 12.87 M

Mr. Scott Ullem

(57)
Edwards Lifesciences Chief Financial Officer, Corporate Vice President
Compensation 5.95 M

Mr. Jean-Luc Lemercier

(67)
Edwards Lifesciences Corporate Vice President, EMEACLA (Europe, Middle East, Africa, Canada and Latin America)
Compensation 5.91 M

Mr. Larry Wood

(58)
Edwards Lifesciences Corporate Vice President and Group President, Transcatheter Aortic Valve Replacement
Compensation 5.4 M

Ms. Catherine Szyman

(57)
Edwards Lifesciences Corporate Vice President - Critical Care
Compensation 4.34 M
1
2
3
4

Edwards Lifesciences Supply Chain

NameRelationshipTwo-week correlationOne-month correlationThree-Month CorrelationSix-Month CorrelationOne Year CorrelationTwo-Year Correlation
SurModics Stock
SurModics
SupplierCustomer0,610,530,750,180,600,78
Mentice AB (publ) Stock
Mentice AB (publ)
SupplierCustomer0,480,750,930,850,780,82
CAE Stock
CAE
SupplierCustomer0,420,87-0,140,050,590,57
Benchmark Electronics Stock
Benchmark Electronics
SupplierCustomer-0,100,70-0,02-0,820,090,28
Carmat Stock
Carmat
SupplierCustomer-0,680,490,710,690,240,68
SEC Newgate S.p.A. Stock
SEC Newgate S.p.A.
SupplierCustomer-0,710,49-0,83-0,32
1

Most common questions regarding Edwards Lifesciences

What values and corporate philosophy does Edwards Lifesciences represent?

Edwards Lifesciences Corp represents values of innovation, patient focus, and global collaboration. The company's corporate philosophy revolves around improving patient lives through its life-saving technologies and innovative medical solutions. Edwards Lifesciences Corp is committed to delivering high-quality, accessible, and cost-effective healthcare solutions worldwide. With a strong emphasis on research and development, the company aims to pioneer breakthrough technologies in heart valve therapies and critical care monitoring. Edwards Lifesciences Corp's dedication to improving patient outcomes, advancing medical science, and enhancing the quality of life sets it apart as a renowned leader in the healthcare industry.

In which countries and regions is Edwards Lifesciences primarily present?

Edwards Lifesciences Corp is primarily present in various countries and regions worldwide. The company has a global presence, with a strong focus on North America, Europe, and the Asia-Pacific region. Their innovative medical technologies for cardiovascular disease management and critical care solutions are utilized by healthcare professionals in hospitals and medical centers across the United States, Canada, Germany, France, the United Kingdom, Japan, China, India, and many other countries. Edwards Lifesciences Corp's commitment to advancing patient care extends to various markets, ultimately benefiting individuals and healthcare systems globally.

What significant milestones has the company Edwards Lifesciences achieved?

Some significant milestones achieved by Edwards Lifesciences Corp include the introduction of the first commercially available artificial heart valve in 1960, the development of the first transcatheter aortic valve system known as SAPIEN in 2002, and the successful launch of the SAPIEN 3 Ultra system in 2015, which showcased improved patient outcomes. Edwards Lifesciences Corp has also achieved regulatory approvals and expanded its product portfolio, providing innovation in heart valve therapy. The company continues to make advancements in medical technology, contributing to improved patient care and enhancing its position in the medical device industry.

What is the history and background of the company Edwards Lifesciences?

Edwards Lifesciences Corp is a medical technology company founded in 1958. It specializes in developing and manufacturing products for patients with cardiovascular disease. With its headquarters in Irvine, California, Edwards Lifesciences Corp has grown to become a leading global player in the healthcare industry. The company is renowned for its innovative heart valves and hemodynamic monitoring systems, which help improve the lives of patients suffering from heart conditions. Edwards Lifesciences Corp has a rich history of pioneering breakthroughs in heart surgery, making it a trusted name in the field of cardiac care.

Who are the main competitors of Edwards Lifesciences in the market?

The main competitors of Edwards Lifesciences Corp in the market include Medtronic, Boston Scientific, and Abbott Laboratories. These companies also operate in the medical devices and equipment industry, offering various products and services related to cardiovascular healthcare. Edwards Lifesciences Corp, a leading player in this sector, faces intense competition from these firms in areas such as heart valve replacement, monitoring systems, and other innovative technologies. However, Edwards Lifesciences Corp has maintained a strong market presence and gained a competitive edge through its exceptional products, continuous advancements, and significant customer trust.

In which industries is Edwards Lifesciences primarily active?

Edwards Lifesciences Corp is primarily active in the healthcare industry, specifically in the field of medical devices. The company specializes in the development and manufacturing of innovative heart valves, monitoring systems, and critical care technologies. With a strong focus on cardiovascular diseases, Edwards Lifesciences Corp offers solutions that improve patient outcomes and quality of life. Leveraging their expertise and cutting-edge technology, the company continues to make significant contributions to the medical industry, addressing the growing need for advanced cardiovascular treatments and therapies.

What is the business model of Edwards Lifesciences?

The business model of Edwards Lifesciences Corp revolves around the development, manufacturing, and marketing of innovative heart valve treatment solutions. Edwards Lifesciences Corp specializes in transcatheter heart valves and critical care technologies, enabling minimally invasive procedures for treating structural heart disease. The company's products aim to improve patient outcomes and enhance healthcare efficiency. Edwards Lifesciences Corp's business model is driven by its commitment to research and development, strategic collaborations, global expansion, and delivering exceptional quality and value to healthcare providers. Edwards Lifesciences Corp consistently strives to meet the evolving needs of patients worldwide through its innovative solutions in the field of cardiovascular disease management.

What is the P/E ratio of Edwards Lifesciences 2025?

The P/E ratio cannot be calculated for Edwards Lifesciences at the moment.

What is the P/S ratio of Edwards Lifesciences 2025?

The P/S cannot be calculated for Edwards Lifesciences currently.

What is the Quality Investing of Edwards Lifesciences?

The Quality Investing for Edwards Lifesciences is 7/10.

What is the revenue of Edwards Lifesciences 2025?

The expected Edwards Lifesciences revenue is 6.16 B USD.

How high is the profit of Edwards Lifesciences 2025?

The expected Edwards Lifesciences profit is 1.54 B USD.

What is the business model of Edwards Lifesciences

Edward Lifesciences Corp is a multinational company that has been developing and producing innovative medical products for heart and vascular diseases for over 60 years. With headquarters in California, USA, the company operates worldwide and employs over 14,000 employees. Edward Lifesciences Corp is a market leader in heart valve and heart monitoring equipment. The company's business model focuses on three main areas: heart valves, hemodynamics, and critical care. In the field of heart valves, the company develops a wide range of products such as biological aortic valves, mechanical aortic valves, transcatheter aortic valve implants (TAVI), mitral valves, and pulmonary valves. These products are used to treat patients with a variety of heart diseases and are known for their high precision, safety, and effectiveness. In the field of hemodynamics, Edward Lifesciences Corp offers products such as catheters, sensors, and monitoring devices for hospitals and clinics. These products help doctors and medical staff to accurately monitor the hemodynamics of patients, especially in the intensive care unit, and to respond quickly and precisely. The critical care division of Edward Lifesciences Corp provides medical devices for monitoring and supporting patients in the intensive care unit. These products include ventilators, blood gas analyzers, and monitoring devices for vital signs. Edward Lifesciences Corp is globally recognized for its research and development and its commitment to the highest standards in medicine. In 1958, Miles "Lowell" Edwards, the founder of the company, invented the first artificial heart valve. Since then, Edward Lifesciences Corp has introduced a variety of innovative products to the market and continues to work on improving the lives of heart patients worldwide. The company is also known for its ability to incorporate the latest technologies into its products. For example, TAVI implants were developed based on the latest innovations in minimally invasive surgery. With the use of state-of-the-art technology and intensive research, the company has established itself as a leading provider of medical devices. Edward Lifesciences Corp is continuously working to improve its business model and incorporate new products and services into its portfolio. The company is not only a leader in research and development but also in the production, marketing, and distribution of its products. Edward Lifesciences Corp is committed to always offering innovative and effective solutions for patients with heart diseases in order to improve their quality of life.

What is the Edwards Lifesciences dividend?

Edwards Lifesciences pays a dividend of 0 USD distributed over payouts per year.

How often does Edwards Lifesciences pay dividends?

The dividend cannot currently be calculated for Edwards Lifesciences or the company does not pay out a dividend.

What is the Edwards Lifesciences ISIN?

The ISIN of Edwards Lifesciences is US28176E1082.

What is the Edwards Lifesciences WKN?

The WKN of Edwards Lifesciences is 936853.

What is the Edwards Lifesciences ticker?

The ticker of Edwards Lifesciences is EW.

How much dividend does Edwards Lifesciences pay?

Over the past 12 months, Edwards Lifesciences paid a dividend of . This corresponds to a dividend yield of about . For the coming 12 months, Edwards Lifesciences is expected to pay a dividend of 0 USD.

What is the dividend yield of Edwards Lifesciences?

The current dividend yield of Edwards Lifesciences is .

When does Edwards Lifesciences pay dividends?

Edwards Lifesciences pays a quarterly dividend. This is distributed in the months of .

How secure is the dividend of Edwards Lifesciences?

Edwards Lifesciences paid dividends every year for the past 0 years.

What is the dividend of Edwards Lifesciences?

For the upcoming 12 months, dividends amounting to 0 USD are expected. This corresponds to a dividend yield of 0 %.

In which sector is Edwards Lifesciences located?

Edwards Lifesciences is assigned to the 'Health' sector.

Wann musste ich die Aktien von Edwards Lifesciences kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Edwards Lifesciences from 10/7/2025 amounting to 0 USD, you needed to have the stock in your portfolio before the ex-date on 10/7/2025.

When did Edwards Lifesciences pay the last dividend?

The last dividend was paid out on 10/7/2025.

What was the dividend of Edwards Lifesciences in the year 2024?

In the year 2024, Edwards Lifesciences distributed 0 USD as dividends.

In which currency does Edwards Lifesciences pay out the dividend?

The dividends of Edwards Lifesciences are distributed in USD.

All fundamentals about Edwards Lifesciences

Our stock analysis for Edwards Lifesciences Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Edwards Lifesciences Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.